Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-473-6 | CAS number: 121-47-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Genetic toxicity in vitro:
- Ames (NIHSJapan2008) -> negativ
- Chromosome abberation(CHO(V79 cells)) (Morita_2012) ->positiv
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant guideline study, published in peer reviewed literature, minor restrictions in design and/or reporting but otherwise adequate for assessment
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Principles of method if other than guideline:
- The main study was conducted in accordance with “Methods of Testing New Chemical Substances” (Kanpogyo No. 237, Yakuhatsu No. 306, and 62 Kikyoku No. 303 Notifications dated March 31, 1987) and OECD Guidelines for the Testing of Chemicals 471 and 472, and based on chemical substance GLP (Kanpogyo No. 39, Yakuhatsu No. 229, and 59 Kikyoku No. 85 Notifications dated March 31, 1984, and Kankiken No. 233, Eisei No. 38, and 63 Kikyoku No. 823 Notifications revised on November 18, 1988).
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Metabolic activation system:
- S-9: Rat liver, induced with phenobarbital and 5,6-benzoflavone
- Test concentrations with justification for top dose:
- 0, 312.5, 625, 1250,2500, 5000 µg/plate
- Vehicle / solvent:
- DMSO
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene
- Remarks:
- Strain TA100, TA1535, TA98, TA1537, E. coli WP2 uvrA, with metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 9-aminoacridine
- Remarks:
- Strain TA 1537 without metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- Strain TA1535 without metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: AF-2
- Remarks:
- Strain TA100, WP2, TA98, without metabolic activation
- Details on test system and experimental conditions:
- Procedures: Plate incorporation method
Plates/test: 3
Number of replicates: 2 - Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Species / strain:
- E. coli WP2
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- No toxicity was observed up to a concentration of 5000 µg/plate with or without metabolic activation.
- Conclusions:
- Gentoxicity: negative
- Executive summary:
A bacterial reverse mutation study was conducted to investigate whether or not 3‑aminobenzenesulfonic acid is mutagenic. Using Salmonella typhimurium TA100, TA1535, TA98 and TA1537, and Escherichia coli WP2 uvrA strains as test bacteria, the dose-setting study and the main study were both conducted by the direct method and by the metabolic activation method, using 50-5000 mg/plate in the dose-setting study and 312.5-5000 mg/plate in the main study. The results revealed no increase in the number of revertant colonies in any of the five strains of test bacteria used, at any dose, in either of the two runs of the main study, and so 3‑aminobenzenesulfonic acid was judged not to be mutagenic in the study system used.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant guideline study, published in peer reviewed literature, minor restrictions in design and/or reporting but otherwise adequate for assessment
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Details on mammalian cell type (if applicable):
- CHL/IU cells used were obtained from Japanese Cancer Research Resources Bank (JCRB).
- Metabolic activation:
- with and without
- Metabolic activation system:
- S-9: Rat liver, induced with phenobarbital and 5,6-benzoflavone
- Test concentrations with justification for top dose:
- -S9 (continuous treatment; 23 and 48 hours): 0, 0.43, 0.85, 1.70 mg/mL
-S9 (short-term treatment; 6- (18) hours): 0, 0.41, 0.83, 1.1, 1.65, 2.2, 4.4 mg/mL
+S9 (short-term treatment; 6- (18) hours): 0, 0.41, 0.83, 1.1, 1.65, 2.2, 4.4 mg/mL - Vehicle / solvent:
- 0.5% Carboxymethyl cellulose sodium
- Untreated negative controls:
- yes
- Remarks:
- At test concentrations 1.1, 2.2, 4.4 without metabolic activation
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- With and without metabolic activation
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- mitomycin C
- Remarks:
- Without metabolic activation
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
Plates/test: 2
DURATION
- Preincubation period:
CHL/IU cells used were obtained from Japanese Cancer Research Resources Bank (JCRB). The cells were cultured with Eagle’ s minimum essential medium MEM, Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal calf serum or calf serum. The 2 x 10^4 cells were plated in 5 mL medium on 60 mm plate and cultured for 72 h at 37°C in a humidified incubator (5% CO2) before the treatment with the test substance.
Chemical treatment:
In order to examine the metabolic activation of the test substance, the proliferating cells were treated with the test substance for 6 h in serum-free MEM with S9 mix (S9(+)), or without S9 mix (S9(-)), then cultured a further 18 h in the fresh MEM with serum. S9 (Kikkoman, Chiba, Japan) and co-factors were mixed immediately before use, then applied to cultures to expose the cells to the S9 at 5% (v/v). Moreover, the cells were also treated with the test substance for 24 and 48 h continuously in the absence of S9 mix. Duplicate cultures were used for each dose.
Growth inhibition test for cytotoxicity evaluation:
Preliminary growth inhibition test was conducted to determine the cytotoxicity of the test substance. Relative cell confluence or cell number to solvent control was measured with a MonocellaterTM (Olympus Optics, Tokyo, Japan) or a Coulter CounterTM (Coulter Electronics, Bedfordshire, UK), respectively. Relative metaphase frequency (relative mitotic index) to the solvent control was also used as an indicator of cytotoxicity when appropriate. A maximum dose was set for the chromosomal aberration test at 50% or more of the cytotoxic dose determined by the growth inhibition test. When cytotoxicity was 50% or less, 5 mg/mL or 10mM was set as the maximum dose. The other doses were sequential half dilutions.
Chromosome preparation:
Before harvesting, the cells were treated with 0.1 µg/mL of colcemid for 2h, then chromosome specimens were made by the usual air-dry method.
Chromosome analysis:
Chromosome specimens were stained with 3% Giemsa solution for 8 min. The number of cells with chromatid- and chromosome-type breaks and exchanges were scored per 200 cells at each dose. Polyploid cells were also scored per 800 cells at each dose. A polyploid cell was defined as a metaphase with more than 37 chromosomes, i.e. theoretical “hypertriploid cell", containing approximately three times the number of chromosomes than half the modal chromosome number (25) in CHL/IU cells. - Evaluation criteria:
- An experiment was classified as(a) positive (+): ≥10% cells with CAs; (b) equivocal (?): ≥ 5 - 10 % cells with CAs, or (c) negative (-): less than 5% cells with CAs.Chemicals showing atleast one positive or equivocal experiment were considered positive or equivocal compound, respectively, in the original report. Statistical significance, reproducibility, culture conditions,or concentration relationship of the response were taken into consideration in some cases. Basically, calls of the classification of a chemical was based on the original calls. However, there are some exceptions to this analysis. lf a chemical was classified equivocal in the original "call" and showed a reproducibility and/or concentration-related response with statistical significance, the chemical was considered positive.
Chemicals that show negative and/or equivocal (without reproducibility or concentration-related response) results were also considered as negative compounds. The percentages of cells with CAs refer to structural aberrations and do not include polyploidy. - Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Remarks:
- short-term treatment: 0.41 and 0.83 mg/mL (clastogenicity)
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- For the test substance tested for 6 h with metabolic activation, the color of the culture medium shifted from orange or red (pH 7-8) to yellow (pH<6) just after applying the treatment solution, suggesting that CA was generated by the non-physiological culture conditions. Culture medium with low pH (pH<6.4) was known to induce structural CA in CHL/IU cells, but it could not be assumed without confirmation that structural CA in the current tests were caused by lowering pH.
At the concentration of 0.41 mg/mL and 0.83 mg/mL short-term treatments with S9 mix resulted in 6.5% and 17% of the cells, respectively demonstrating structural aberrations (including gaps). However, it was suggested that acidic pH may have been related to the induction of chromosomal aberration.
Lowest concentration producing cytogenetic effects in vitro:
without metabolic activation (continuous treatment ): > 1.70 mg/mL
without metabolic activation (short-term treatment): > 4.4 mg/mL
with metabolic activation (short-term treatment): 0.41 mg/mL (clastogenicity)
Genotoxic effects:
without metabolic activation: clastogenicity (-); polyploidy (-)
with metabolic activation: clastogenicity (+); polyploidy(-) - Conclusions:
- Gentoxicity (chinese hamster lung fibroblasts(V/79): Result is positive (with metabolic acitvation) and negativ (without metabolic activation).
- Executive summary:
Results described by Morita T., et al.
3-Aminobezenesulfonic acid induced CAs with S9 mix (5.0 and 16.5% at 2.4 and 4.8 mM (0.83 mg/mL), respectively). The pH of the medium was 5.8 or 6.3 at the beginning of the 6-h treatment and 6.2 or 6.5 just after it at 4.8 or 2.4 mM. respectively. Relative cell growth, as measured by monolayer confluence, was about 100% or 90% at 4.8 or 9.5 mM, respectively. However, there were no metaphases at 9.5 mM. Without S9 mix, no CA induction was observed after 6- or 24-h treatment. The reason for this will be due to the short duration in Iow pH culture condition: the pH of the medium without S9 mix was 5.8 or 6.5 at the beginning of the 6-h treatment and 6.6 or 6.9 just after it at 4.8 or 2.4 mM, respectively. Initial pHs of the medium were similar, but the pHs after the treatment without S9 mix were higher than that with S9 mix. The window of the induction of CAs by Iow pH is narrower without S9 mix than that with S9 mix, generally. 3-Aminobenzenesulfonic acid does not possess any DEREK structural alerts. The CAs observed are considered as irrelevant as they were only seen at low pH. and it is supported by all other available data. Thus the Ievel of concern is negligible.
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Genetic toxicity in vivo
Description of key information
Gentic toxicity in vivo:
- MNT (OECD 474) (BioZoResCent(Japan)) -> negativ
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / bone marrow chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2011 - 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- yes
- Type of assay:
- mammalian erythrocyte micronucleus test
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source (i.e. manufacturer or supplier) and lot/batch number of test material: 45JPG
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
The test substance was analyzed by the study consignee on completion of the animal study, and was confirmed as having been stable throughout the period of the animal study
- Storage condition of test material: Cool dark place (measured value: 2-8°C), tightly sealed - Species:
- mouse
- Strain:
- CD-1
- Details on species / strain selection:
- SPF mice [Crlj:CD1(ICR), Atsugi Breeding Center, Charles River Laboratories Japan, Inc.]
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Institute of Cancer Research
- Age at study initiation: 7 weeks
- Weight at study initiation: 35.8-41.6 g for the males and 28.7-32.2 g for the females
- Assigned to test groups randomly: [no/yes, under following basis: ] yes
- Housing: The animals were housed individually in plastic cages (W 155 D 245 H 150 mm Clea Japan Inc.) provided with floor covering (white flake, Charles River Laboratories Japan), in an animal rearing room (Rearing Room Number: Room 101 for preliminary study,
- Diet (e.g. ad libitum): . Solid feed CRF-1 (Oriental Yeast )Co., Lot No. 110908
- Water (e.g. ad libitum): drinking water (Gotemba City tap water, using water bottles)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24°C
- Humidity (%): (acceptable range 50±20%) 46-56% for the preliminary study and 42-55% for the main study
- Air changes (per hr): 10-15 times per hour
- Photoperiod (hrs dark / hrs light): 12 hours a day (07:00-19:00)/12 hours dark (19:00-7:00)
- Route of administration:
- oral: unspecified
- Vehicle:
- Sodium carboxymethylcellulose
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Dose / conc.:
- 2 000 mg/kg bw/day (nominal)
- Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- 3-Aminobenzenesulfonic acid was administered at 250, 500, 1000 and 2000 mg/kg/day.. On observation of the general condition, colored urine (orange-yellow) was observed in all males and females in each test substance administration group. There were no deaths. No decrease in body weight related to test substance administration was observed. There were no observed changes in general condition in the negative control group or in the positive control group. There were no observed abnormalities in body weight variation in any test substance administration group compared to the negative control group. There were no observed abnormalities in body weight variation in the positive control group. In the test substance administration groups, the MNPCE frequency was 0.12 ± 0.08% in the 500 mg/kg/day group, 0.14 ± 0.11% in the 1000 mg/kg/day group and 0.11 ± 0.04% in the 2000 mg/kg/day group. Comparing these values with the negative control group of 0.11 ±0.05%, no statistically significant increase or dose dependent change was observed in any of the test substance administration groups. There were no statistically significant (p<0.05) changes in the PCE frequency in 200 total erythrocytes in any test substance administration group compared to the negative control group. The MNPCE frequency in the positive control group was markedly higher than in the negative control group. Furthermore, the MNPCE frequencies in the negative control group and the positive control group were within the range of mean ± 3 S.D. of the study laboratory background data.
- Executive summary:
A micronucleus study was conducted using Crlj:CD1(ICR) SPF mice, in order to investigate whether or not 3-aminobenzenesulfonic acid induces chromosomal aberration. In the preliminary study for determining the doses, 250, 500, 1000 and 2000 mg/kg/day,respectively, was administered orally twice at an interval of about 24 hours, to 3 males and 3 females in each group; observation of general condition revealed that, as a result, all males and females in each test substance administration group exhibited colored urine (orange-yellow). There were no deaths. There were no decreases in body weight relating to test substance administration. Based on the above results, there were no deaths in the preliminary study wherein the maximum dose was 2000 mg/kg/day, and so in the main study, 2000 mg/kg/day was set as the high dose, and this was divided by a common ratio of 2 to give doses of 1000 and 500 mg/kg/day; these doses were administered orally twice at an interval of about 24 hours. Bone marrow smear samples were produced and observed about 24 hours after the second administration. Moreover, a negative control group and a positive control group were established; the negative control group received aqueous 0.5% CMC-Na solution at the same administration frequency as in the test substance administration group, and the positive control received a single administration of 1 mg/kg mitomycin C, and at the prescribed time after administration, bone marrow smear samples were prepared and observed. Five male animals were used per group. The results revealed no statistically significant increase in MNPCE frequency in any test substance administration group compared to the negative control group, and no dose-dependent changes were observed. Furthermore, there was no statistically significant change in the PCE frequency in 200 total erythrocytes in any test substance administration group compared to the negative control group. The MNPCE frequencies in the negative control and positive control groups were within the range of mean ± 3 S.D. of the study laboratory background data, and so the test was thought to have been conducted appropriately. It was judged from the above results that, under the conditions of this study, 3-aminobenzenesulfonic acid does not induce chromosomal aberration in the bone marrow of Crlj:CD1(ICR) SPF mice.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
In a GLP complaint study according to the Japanese Guidelines for Screening Mutagenicity Testing of Chemicals, 3-aminobenzenesulfonic acid was investigated using the Salmonella/microsome test for point mutagenic effects in doses of up to 5000 µg per plate with five S.typhimurium TA100, TA1535, TA98, TA1537, E. coli WP2 uvrA test species. No toxicity was observed up to a concentration of 5000 µg/plate with or without metabolic activation.
In a GLP compliant study performed according to OECD 471, 3-aminobenzenesulfonic acid was investigated using the Salmonella/microsome test for point mutagenic effects in doses of up to 5000 µg per plate en four Salmonella typhimurium LT2 mutants (Bayer AG 1992). These comprised the histidine-auxotrophic strains TA 1535, TA 100, TA 1537 and TA 98. Doses of up to and including 200 μg per plate did not cause any bacteriotoxic effects: Total bacteria counts remained unchanged and no inhibition of growth was observed. At higher doses, the substance had a weak strain-specific bacteriotoxic effect, so that this range could nevertheless be used for assessment purposes.
In a GLP complaint study according to the Japanese Guidelines for Screening Mutagenicity Testing of Chemicals, 3-aminobenzenesulfonic acid was tested in the in vitro chromosomal aberration test in Chinese hamser CHL/IU cells (NIHS 2008, Morita 2012, Kusakabe 2002). In order to examine the metabolic activation of the test substance, the proliferating cells were treated with the test substance for 6 h in serum-free MEM with S9 mix (S9(+)), or without S9 mix (S9(-)), then cultured a further 18 h in the fresh MEM with serum. Moreover, the cells were also treated with the test substance for 24 and 48 h continuously in the absence of S9 mix. Duplicate cultures were used for each dose. For the test substance tested for 6 h with metabolic activation, the color of the culture medium shifted from orange or red (pH 7-8) to yellow (pH<6) just after applying the treatment solution, suggesting that CA was generated by the non-physiological culture conditions. Culture medium with low pH (pH<6.4) was known to induce structural CA in CHL/IU cells, but it could not be assumed without confirmation that structural CA in the current tests were caused by lowering pH. At the concentration of 0.41 mg/mL and 0.83 mg/mL short-term treatments with S9 mix resulted in 6.5% and 17% of the cells, respectively demonstrating structural aberrations (including gaps). However, it was suggested that acidic pH may have been related to the induction of chromosomal aberration.
Lowest concentration producing cytogenetic effects in vitro:
without metabolic activation (continuous treatment ): > 1.70 mg/mL
without metabolic activation (short-term treatment): > 4.4 mg/mL
with metabolic activation (short-term treatment): 0.41 mg/mL (clastogenicity) 3-Aminobezenesulfonic acid induced CAs with S9 mix (5.0 and 16.5% at 2.4 and 4.8 mM (0.83 mg/mL), respectively). The pH of the medium was 5.8 or 6.3 at the beginning of the 6-h treatment and 6.2 or 6.5 just after it at 4.8 or 2.4 mM. respectively. Relative cell growth, as measured by monolayer confluence, was about 100% or 90% at 4.8 or 9.5 mM, respectively. However, there were no metaphases at 9.5 mM. Without S9 mix, no CA induction was observed after 6- or 24-h treatment. The reason for this will be due to th short duration in Iow pH culture condition: the pH of the medium without S9 mix was 5.8 or 6.5 at the beginning of the 6-h treatment and 6.6 or 6.9 just after it at 4.8 or 2.4 mM, respectively. Initial pHs of the medium were similar, but the pHs after the treatment without S9 mix were higher than that with S9 mix. The window of the induction of CAs by Iow pH is narrower without S9 mix than that with S9 mix, generally. 3-Aminobenzenesulfonic acid does not possess any DEREK structural alerts. The CAs observed are considered as irrelevant as they were only seen at low pH and it is supported by all other available data. Thus the Ievel of concern is negligible.
In a GLP compliant study performed according to OECD 474, 3-aminobenzenesulfonic acid was administered at 250, 500, 1000 and 2000 mg/kg/day. On observation of the general condition, colored urine (orange-yellow) was observed in all males and females in each test substance administration group. There were no deaths. No decrease in body weight related to test substance administration was observed. There were no observed changes in general condition in the negative control group or in the positive control group. There were no observed abnormalities in body weight variation in any test substance administration group compared to the negative control group. There were no observed abnormalities in body weight variation in the positive control group. In the test substance administration groups, the MNPCE frequency was 0.12 ± 0.08% in the 500 mg/kg/day group, 0.14 ± 0.11% in the 1000 mg/kg/day group and 0.11 ± 0.04% in the 2000 mg/kg/day group. Comparing these values with the negative control group of 0.11 ±0.05%, no statistically significant increase or dose dependent change was observed in any of the test substance administration groups. There were no statistically significant (p<0.05) changes in the PCE frequency in 200 total erythrocytes in any test substance administration group compared to the negative control group. The MNPCE frequency in the positive control group was markedly higher than in the negative control group. Furthermore, the MNPCE frequencies in the negative control group and the positive control group were within the range of mean ± 3 S.D. of the study laboratory background data.
Short description of key information:
3-Aminobenzenesulfonic acid was considered to be non-mutagenic in the Salmonella/microsome test, without and with S9 mix.
3-Aminobezenesulfonic acid induced CAs with S9 mix in the in vitro Chromosomal Aberration test. However, the aberration may be induced by acidity and may not be linked to physiological DNA damage.
3-Aminobenzenesulfonic acid was considered to be non-mutagenic in the in vivo MNT.
Endpoint Conclusion:
Although 3-Aminobenzenesulfonic acid was positive in vitro, such an effect has not been observed in vivo. All in all, the substance is considered negativ.
Justification for classification or non-classification
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance is considered not to be classified for genetic toxicity under Regulation (EC) No. 1272/2008, as amended for the 13th time in Regulation (EU) 2018/1480.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
